Biofrontera, Inc. (BFRI)
1.56
0.00 (0.00%)
USD |
NASDAQ |
Sep 09, 15:35
Biofrontera Debt to Equity Ratio : 1.260 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.260 |
| March 31, 2026 | 1.272 |
| December 31, 2025 | 0.5879 |
| September 30, 2025 | -1.900 |
| June 30, 2025 | -1.072 |
| March 31, 2025 | 10.37 |
| December 31, 2024 | 1.110 |
| September 30, 2024 | 0.1797 |
| June 30, 2024 | 0.132 |
| March 31, 2024 | -1.336 |
| December 31, 2023 | 1.126 |
| Date | Value |
|---|---|
| September 30, 2023 | 2.711 |
| June 30, 2023 | 0.306 |
| March 31, 2023 | 0.0722 |
| December 31, 2022 | 0.0564 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ANI Pharmaceuticals, Inc. | 1.022 |
| Corcept Therapeutics, Inc. | 0.0133 |
| Veru, Inc. | 0.0945 |
| Johnson & Johnson | 0.5771 |
| Eli Lilly & Co. | 1.621 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 24.06M |
| Total Liabilities (Quarterly) | 18.11M |
| Shareholders Equity (Quarterly) | 5.956M |
| Current Ratio | 1.180 |
| Net Debt Paydown Yield | -3.93% |